Trial · NCT06423911
Study of Olverembatinib (HQP1351) in Patients With CML-CP
NCT06423911, Phase 3, Recruiting, Ascentage Pharma Group Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Olverembatinib (HQP1351) in Patients With CML-CP. Trials, record NCT06423911. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06423911
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Olverembatinib (HQP1351) in Patients With CML-CP
- NCT number
- NCT06423911
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 333 participants, estimated
- Lead sponsor
- Ascentage Pharma Group Inc.
- Conditions
- Chronic Myeloid Leukemia, CML, CML, Chronic Phase
- Interventions
- olverembatinib, Bosutinib
- First posted
- 2024-05-21
- Last updated
- 2026-09-15
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 24-Week MMR Rate (Part A) | 24 weeks | To compare the major molecular response (MMR) rate at 24 weeks for olverembatinib versus bosutinib |
| Primary | 24-Week MMR Rate (Part B) | 24 weeks | To evaluate the MMR rate by 24 weeks for olverembatinib in CML-CP patients with T315I mutation |
| Secondary | 96-Week MMR Rate (Part A) | 96 weeks | To compare the major molecular response (MMR) rate at 96 weeks for olverembatinib versus bosutinib |
| Secondary | 96-Week MMR Rate (Part B) | 96 weeks | To evaluate the major molecular response (MMR) rate by 96 weeks for olverembatinib in CML-CP patients with T315I mutation |
| Secondary | Cytogenic Response Rate (Part A) | Through 96 weeks (i.e., at 24, 48, and 96 weeks) | To compare the complete cytogenic response rate at all scheduled data collection time points for olverembatinib vs. bosutinib. |
| Secondary | Cytogenic Response Rate (Part B) | Through 96 weeks (i.e., at 24, 48, and 96 weeks) | To evaluate the complete cytogenic response rate at all scheduled data collection time points for olverembatinib in CML-CP patients with T315I mutation |
| Secondary | Progression Free Survival (PFS) (Part A) | 5 years after the last patient received the first study dose | To compare duration of PFS (i.e., from the date of randomization to the earliest occurrence of documented disease progression to AP/BP or the date of death from any cause) for olverembatinib versus bosutinib |
| Secondary | Progression Free Survival (PFS) (Part B) | 5 years after the last patient received the first study dose | To evaluate duration of PFS (i.e., from the date of enrollment to the earliest occurrence of documented disease progression to AP/BP or the date of death from any cause) for olverembatinib in CML-CP patients with T315I mutation |
| Secondary | Overall Survival (OS) (Part A) | 5 years after the last patient received the first study dose | To compare OS (duration from date of randomization to date of death) for olverembatinib versus bosutinib |
| Secondary | Overall Survival (OS) (Part B) | 5 years after the last patient received the first study dose | To evaluate OS (duration from date of randomization to date of death) for olverembatinib in CML-CP patients with T315I mutation |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06423911
GET https://conductscience.org/api/trials/v1/NCT06423911/registered